To include your compound in the COVID-19 Resource Center, submit it here.

BioPhausia, Medivir deal

Medivir will acquire specialty pharma BioPhausia in a cash and stock deal that values BioPhausia at SEK1.65 per

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE